Pear Therapeutics, Inc. reaffirmed revenue guidance for the full year 2022. For the year, reaffirmed its $22 million revenue guidance.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
05-23 | Pear Therapeutics, Inc. Went Out of Business | CI |
05-08 | Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142 | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- PEAR Stock
- News Pear Therapeutics, Inc.
- Pear Therapeutics Reaffirms Revenue Guidance for the Full Year 2022